<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Regeneron Pharmaceuticals Inc. shares REGN, +2.09% rose 1.8% in premarket trade Thursday, after the company blew past estimates for the third quarter and said the U.S. government has ordered another 1.4 million doses of its COVID-19 antibody treatment. The company posted net income of $1.632 billion, or $14.33 a share, for the quarter, or almost double the $842 million, or $7.39 a share, in the year-earlier period.
...read full article on Market Watch
